|
1
|
McGarrity TJ and Amos C: Peutz-Jeghers
syndrome: Clinicopathology and molecular alterations. Cell Mol Life
Sci. 63:2135–2144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hearle N, Schumacher V, Menko FH,
Olschwang S, Boardman LA, Gille JJ, Keller JJ, Westerman AM, Scott
RJ, Lim W, et al: Frequency and spectrum of cancers in the
Peutz-Jeghers syndrome. Clin Cancer Res. 12:3209–3215. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ji H, Ramsey MR, Hayes DN, Fan C, McNamara
K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, et al:
LKB1 modulates lung cancer differentiation and metastasis. Nature.
448:807–810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lizcano JM, Göransson O, Toth R, Deak M,
Morrice NA, Boudeau J, Hawley SA, Udd L, Mäkelä TP, Hardie DG, et
al: LKB1 is a master kinase that activates 13 kinases of the AMPK
subfamily, including MARK/PAR-1. EMBO J. 23:833–843. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alessi DR, Sakamoto K and Bayascas JR:
LKB1-dependent signaling pathways. Annu Rev Biochem. 75:137–163.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ylikorkala A, Rossi DJ, Korsisaari N,
Luukko K, Alitalo K, Henkemeyer M and Mäkelä TP: Vascular
abnormalities and deregulation of VEGF in Lkb1-deficient mice.
Science. 293:1323–1326. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jishage K, Nezu J, Kawase Y, Iwata T,
Watanabe M, Miyoshi A, Ose A, Habu K, Kake T, Kamada N, et al: Role
of Lkb1, the causative gene of Peutz-Jegher's syndrome, in
embryogenesis and polyposis. Proc Natl Acad Sci USA. 99:8903–8908.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Williams T and Brenman JE: LKB1 and AMPK
in cell polarity and division. Trends Cell Biol. 18:193–198. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hardie DG: AMPK - sensing energy while
talking to other signaling pathways. Cell Metab. 20:939–952. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sebbagh M, Olschwang S, Santoni MJ and
Borg JP: The LKB1 complex-AMPK pathway: The tree that hides the
forest. Fam Cancer. 10:415–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dasgupta B and Chhipa RR: Evolving lessons
on the complex role of AMPK in normal physiology and cancer. Trends
Pharmacol Sci. 37:192–206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fogarty S, Ross FA, Ciruelos D Vara, Gray
A, Gowans GJ and Hardie DG: AMPK causes cell cycle arrest in
LKB1-deficient cells via activation of CAMKK2. Mol Cancer Res.
14:683–695. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang HW, Lee YS, Nam HY, Han MW, Kim HJ,
Moon SY, Jeon H, Park JJ, Carey TE, Chang SE, et al: Knockdown of
β-catenin controls both apoptotic and autophagic cell death through
LKB1/AMPK signaling in head and neck squamous cell carcinoma cell
lines. Cell Signal. 25:839–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang X, Wang P, Gao Q and Tao X:
Exogenous activation of LKB1/AMPK signaling induces G1 arrest in
cells with endogenous LKB1 expression. Mol Med Rep. 9:1019–1024.
2014.PubMed/NCBI
|
|
15
|
Okada T, Sinha S, Esposito I, Schiavon G,
López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M,
et al: The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT
by restraining Ras-MAPK signalling. Nat Cell Biol. 17:81–94. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen N, Balasenthil S, Reuther J and
Killary AM: DEAR1, a novel tumor suppressor that regulates cell
polarity and epithelial plasticity. Cancer Res. 74:5683–5689. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mohseni M, Sun J, Lau A, Curtis S,
Goldsmith J, Fox VL, Wei C, Frazier M, Samson O, Wong KK, et al: A
genetic screen identifies an LKB1-MARK signalling axis controlling
the Hippo-YAP pathway. Nat Cell Biol. 16:108–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shelly M and Poo MM: Role of LKB1-SAD/MARK
pathway in neuronal polarization. Dev Neurobiol. 71:508–527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee S, Wang JW, Yu W and Lu B:
Phospho-dependent ubiquitination and degradation of PAR-1 regulates
synaptic morphology and tau-mediated Aβ toxicity in Drosophila. Nat
Commun. 3:13122012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matenia D and Mandelkow EM: The tau of
MARK: A polarized view of the cytoskeleton. Trends Biochem Sci.
34:332–342. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Müller J, Ritt DA, Copeland TD and
Morrison DK: Functional analysis of C-TAK1 substrate binding and
identification of PKP2 as a new C-TAK1 substrate. EMBO J.
22:4431–4442. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang X, Xu G, Gao Q and Tao X: LKB1
expression reverses the tumorigenicity of L02 cells. Oncol Rep.
36:1055–1061. 2016.PubMed/NCBI
|
|
23
|
Liang X, Wang P, Gao Q, Xiang T and Tao X:
Endogenous LKB1 knockdown accelerates G1/S transition through p53
and p16 pathways. Cancer Biol Ther. 9:156–160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ladhani O, Sánchez-Martinez C, Orgaz JL,
Jimenez B and Volpert OV: Pigment epithelium-derived factor blocks
tumor extravasation by suppressing amoeboid morphology and
mesenchymal proteolysis. Neoplasia. 13:633–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tiainen M, Vaahtomeri K, Ylikorkala A and
Mäkelä TP: Growth arrest by the LKB1 tumor suppressor: Induction of
p21WAF1/CIP1. Hum Mol Genet. 11:1497–1504. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fogarty S and Hardie DG: C-terminal
phosphorylation of LKB1 is not required for regulation of
AMP-activated protein kinase, BRSK1, BRSK2, or cell cycle arrest. J
Biol Chem. 284:77–84. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gopinath P and Ghosh SS: Apoptotic
induction with bifunctional E.coli cytosine deaminase-uracil
phosphoribosyltransferase mediated suicide gene therapy is
synergized by curcumin treatment in vitro. Mol Biotechnol.
39:39–48. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee CJ, Jang JH, Lee JY, Lee MH, Li Y, Ryu
HW, Choi KI, Dong Z, Lee HS, Oh SR, et al: Aschantin targeting on
the kinase domain of mammalian target of rapamycin suppresses
epidermal growth factor-induced neoplastic cell transformation.
Carcinogenesis. 36:1223–1234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sclafani RA and Holzen TM: Cell cycle
regulation of DNA replication. Annu Rev Genet. 41:237–280. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tiainen M, Ylikorkala A and Mäkelä TP:
Growth suppression by Lkb1 is mediated by a G1 cell cycle arrest.
Proc Natl Acad Sci USA. 96:9248–9251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gurumurthy S, Hezel AF, Sahin E, Berger
JH, Bosenberg MW and Bardeesy N: LKB1 deficiency sensitizes mice to
carcinogen-induced tumorigenesis. Cancer Res. 68:55–63. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cánepa ET, Scassa ME, Ceruti JM, Marazita
MC, Carcagno AL, Sirkin PF and Ogara MF: INK4 proteins, a family of
mammalian CDK inhibitors with novel biological functions. IUBMB
Life. 59:419–426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Manning AL and Dyson NJ: pRB, a tumor
suppressor with a stabilizing presence. Trends Cell Biol.
21:433–441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pei XH and Xiong Y: Biochemical and
cellular mechanisms of mammalian CDK inhibitors: A few unresolved
issues. Oncogene. 24:2787–2795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pei XH and Xiong Y: Biochemical and
cellular mechanisms of mammalian CDK inhibitors: A few unresolved
issues. Oncogene. 24:2787–2795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oei AL, van Leeuwen CM, ten Cate R,
Rodermond HM, Buist MR, Stalpers LJ, Crezee J, Kok HP, Medema JP
and Franken NA: Hyperthermia selectively targets human
papillomavirus in cervical tumors via p53-dependent apoptosis.
Cancer Res. 75:5120–5129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Setogawa T, Shinozaki-Yabana S, Masuda T,
Matsuura K and Akiyama T: The tumor suppressor LKB1 induces p21
expression in collaboration with LMO4, GATA-6, and Ldb1. Biochem
Biophys Res Commun. 343:1186–1190. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Aktories K: Bacterial protein toxins that
modify host regulatory GTPases. Nat Rev Microbiol. 9:487–498. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mokady D and Meiri D: RhoGTPases - A novel
link between cytoskeleton organization and cisplatin resistance.
Drug Resist Updat. 19:22–32. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Savagner P: The epithelial-mesenchymal
transition (EMT) phenomenon. Ann Oncol. 21 Suppl 7:vii89–vii92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gandalovičová A, Vomastek T, Rosel D and
Brábek J: Cell polarity signaling in the plasticity of cancer cell
invasiveness. Oncotarget. 7:25022–25049. 2016.PubMed/NCBI
|
